Experience

• • Kelso & Company in the formation of Kelso Investment Associates XI Fund, a $3.25 billion fund.
  • Clayton, Dubilier & Rice in the formation of Clayton, Dubilier & Rice Fund XII, an approximately $26 billion fund, its largest fund to date.
  • Clayton, Dubilier & Rice in the sale of its investment in Belron, a worldwide leader in vehicle glass repair and replacement, valuing the company at €21 billion, including the formation of a new special purpose vehicle formed to continue CD&R’s partnership with Belron. The transaction was named “Secondaries Deal of the Year” by Buyouts magazine.
  • Clayton, Dubilier & Rice in the formation of Clayton, Dubilier & Rice Fund XI, a $16 billion North America and Western Europe fund.
  • Kelso & Company in the formation of Kelso Investment Associates X, a $2.75 billion U.S. buyout fund.
  • A leading international private equity firm in the creation of a novel structured finance product which raised $700 million from various investors in the form of rated notes and equity. The transaction was structured to address insurance company risk-based capital charges when investing across a diverse portfolio of alternative fund products.
  • A Japanese utility as a member of an investor group in the group’s acquisition of majority ownership interests in Kleen Energy Systems, LLC, which operates a 620-megawatt natural gas-fired power plant located in Middletown, Connecticut. As part of the transaction, an affiliate of Ares EIF will manage the Kleen Energy power plant on behalf of the investor group.
  • TPG and Welsh, Carson, Anderson & Stowe in the $4.1 billion acquisition of Kindred Healthcare.
  • Discovery, Inc. in its $14.6 billion acquisition of Scripps Networks Interactive.
  • The Special Committee of the Board of Directors of BGC Partners in BGC Partners’ acquisition of Berkeley Point Financial, a leading commercial real estate finance company.
  • Johnson & Johnson in its purchase of an exclusive option to acquire Bird Rock Bio, a clinical stage biopharmaceutical company focused on innovative immuno-inflammatory regulators that can be used in the treatment of liver disease.